Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Solid Tumor

In brief

This study is an open-label, multicenter, Phase I/IIa, dose escalation, safety, and pharmacokinetics (PK) study of BNT142 followed by expansion cohorts in patients with Claudin 6 (CLDN6)-positive advanced tumors.

Key facts

Study ID
NCT05262530
Run by
BioNTech SE
People needed
73
Starts
2022-03-22
Expected to finish
2025-12-22
Last updated by the study team
2026-04-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.